Julia M Shi1,2, Susan P Henry2, Stephanie L Dwy2, Skye A Orazietti2, Kathleen M Carroll1,3. 1. Department of Internal Medicine, Yale University School of Medicine , New Haven , Connecticut , USA. 2. Central Medical Unit, The APT Foundation , New Haven , Connecticut , USA. 3. Department of Psychiatry, Yale University School of Medicine , New Haven , Connecticut , USA.
Abstract
Background: Despite the clear success of office-based buprenorphine treatment in increasing availability of effective treatment for opioid use disorder, constraints on its effectiveness include high attrition and limited high-quality behavioral care in many areas. Web-based interventions may be a novel strategy for providing evidence-based behavioral care to individuals receiving office-based buprenorphine maintenance. This report describes modification and initial pilot testing of Web-based training in cognitive-behavioral therapy (CBT4CBT) specifically for use with individuals in office-based buprenorphine. Methods: Twelve-week randomized pilot trial evaluating effects of CBT4CBT-Buprenophine in retaining participants and reducing drug use with respect to standard office-based buprenorphine alone was carried out. Twenty individuals meeting DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition) criteria for current opioid use disorder were randomized to standard buprenorphine treatment or buprenorphine plus access to CBT4CBT-Buprenorphine. Results: There were promising findings regarding rates of urine toxicology screens negative for opioids (91% versus 64%; P = .05, effect size d = 0.88) and all drugs (82% versus 30%; P = .004, d = 1.2). Individuals randomized to CBT4CBT-Buprenorphine completed a mean of 82.6 (SD = 4.4) days of treatment (of a possible 84) compared with 68.6 (SD = 32.6) for those assigned to standard buprenorphine treatment. Conclusions: Although preliminary and limited by the small sample size, this trial suggests the feasibility and promise of validated, Web-based interventions, tailored for this specific patient population, for improving outcomes in office-based buprenorphine.
Background: Despite the clear success of office-based buprenorphine treatment in increasing availability of effective treatment for opioid use disorder, constraints on its effectiveness include high attrition and limited high-quality behavioral care in many areas. Web-based interventions may be a novel strategy for providing evidence-based behavioral care to individuals receiving office-based buprenorphine maintenance. This report describes modification and initial pilot testing of Web-based training in cognitive-behavioral therapy (CBT4CBT) specifically for use with individuals in office-based buprenorphine. Methods: Twelve-week randomized pilot trial evaluating effects of CBT4CBT-Buprenophine in retaining participants and reducing drug use with respect to standard office-based buprenorphine alone was carried out. Twenty individuals meeting DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition) criteria for current opioid use disorder were randomized to standard buprenorphine treatment or buprenorphine plus access to CBT4CBT-Buprenorphine. Results: There were promising findings regarding rates of urine toxicology screens negative for opioids (91% versus 64%; P = .05, effect size d = 0.88) and all drugs (82% versus 30%; P = .004, d = 1.2). Individuals randomized to CBT4CBT-Buprenorphine completed a mean of 82.6 (SD = 4.4) days of treatment (of a possible 84) compared with 68.6 (SD = 32.6) for those assigned to standard buprenorphine treatment. Conclusions: Although preliminary and limited by the small sample size, this trial suggests the feasibility and promise of validated, Web-based interventions, tailored for this specific patient population, for improving outcomes in office-based buprenorphine.
Authors: Brian D Kiluk; Charla Nich; Matthew B Buck; Kathleen A Devore; Tami L Frankforter; Donna M LaPaglia; Srinivas B Muvvala; Kathleen M Carroll Journal: Am J Psychiatry Date: 2018-05-24 Impact factor: 18.112
Authors: Kathleen M Carroll; Charla Nich; Elise E DeVito; Julia M Shi; Mehmet Sofuoglu Journal: J Clin Psychiatry Date: 2018 Jan/Feb Impact factor: 4.384
Authors: Kathleen M Carroll; Samuel A Ball; Steve Martino; Charla Nich; Theresa A Babuscio; Kathryn F Nuro; Melissa A Gordon; Galina A Portnoy; Bruce J Rounsaville Journal: Am J Psychiatry Date: 2008-05-01 Impact factor: 18.112
Authors: Julie Netherland; Michael Botsko; James E Egan; Andrew J Saxon; Chinazo O Cunningham; Ruth Finkelstein; Mark N Gourevitch; John A Renner; Nancy Sohler; Lynn E Sullivan; Linda Weiss; David A Fiellin Journal: J Subst Abuse Treat Date: 2008-08-20
Authors: Jessica J Wyse; Benjamin J Morasco; Jacob Dougherty; Beau Edwards; Devan Kansagara; Adam J Gordon; P Todd Korthuis; Anaïs Tuepker; Stephan Lindner; Katherine Mackey; Beth Williams; Anders Herreid-O'Neill; Robin Paynter; Travis I Lovejoy Journal: Drug Alcohol Depend Date: 2021-07-29 Impact factor: 4.852
Authors: Sarah E Lord; Aimee N C Campbell; Mary F Brunette; Leonardo Cubillos; Sophia M Bartels; William C Torrey; Ardis L Olson; Steven H Chapman; John A Batsis; Daniel Polsky; Edward V Nunes; Katherine M Seavey; Lisa A Marsch Journal: JMIR Ment Health Date: 2021-01-28
Authors: Yoram Vodovotz; Neal Barnard; Frank B Hu; John Jakicic; Liana Lianov; David Loveland; Daniel Buysse; Eva Szigethy; Toren Finkel; Gwendolyn Sowa; Paul Verschure; Kim Williams; Eduardo Sanchez; Wayne Dysinger; Victoria Maizes; Caesar Junker; Edward Phillips; David Katz; Stacey Drant; Richard J Jackson; Leonardo Trasande; Steven Woolf; Marcel Salive; Jeannette South-Paul; Sarah L States; Loren Roth; Gary Fraser; Ron Stout; Michael D Parkinson Journal: Front Med (Lausanne) Date: 2020-12-22